I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

Launched by MIAMI CANCER RESEARCH CENTER, INC. · May 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique called I-124 PET/CT to help doctors better understand and treat thyroid cancer. The goal is to see how well this imaging can identify leftover cancer tissue, determine if cancer has spread, and evaluate how patients respond to treatments. It focuses on patients who have had their thyroid gland removed (total thyroidectomy) and may have either newly diagnosed thyroid cancer or concerns about recurring or spreading cancer. The trial also looks at patients who are receiving targeted treatments called thyroid kinase inhibitors (TKIs).

To participate, you must be at least 18 years old, have been diagnosed with thyroid cancer, and be willing to provide written consent. You should also have a life expectancy of more than three months and be in relatively good health. The trial is currently recruiting participants, and those who join can expect to undergo various imaging tests and assessments to monitor their condition before and after treatment. This study aims to improve the way doctors manage thyroid cancer and offer better treatment options for patients.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Post-total thyroidectomy patients with diagnosis of thyroid cancer, any histology, subtype, any ATA risk category, for evaluation for residual disease, cervical or remote metastatic disease
• • Patients with known or suspected recurrent/metastatic thyroid cancer, identified by ultrasound (US), CT/MR/FDG-PET\|CT or elevated thyroglobulin (Tg).
• • Pretreatment and post-treatment evaluation of patients with thyroid cancer deemed RAI-indifferent/refractory who are considered for TKI
• • Age ≥ 18
• • Ability and willingness to give a written consent
• • Life expectancy \> 3 months
• • ECOG performance status ≤ 2
• • Exclusion Criteria
• • Cancers metastatic to thyroid
• • Age \< 18
• • Inability or unwillingness to give a written consent
• • Life expectancy \< 3 months
• • ECOG performance status ≥ 3
• • Pregnant and nursing women.